Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN AND DEXAMETHASONE versus QUIXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN AND DEXAMETHASONE versus QUIXIN.
CIPROFLOXACIN AND DEXAMETHASONE vs QUIXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication and transcription. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
Quixin (levofloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
4 drops into affected ear(s) twice daily for 7 days. Otic suspension; shake well before use.
One to two drops in affected eye(s) every 2 hours while awake, up to 8 times daily for 7-14 days.
None Documented
None Documented
Ciprofloxacin: 3.7-4.3 hours (prolonged in renal impairment). Dexamethasone: 3-4 hours.
Terminal elimination half-life: 6–8 hours in adults with normal renal function; prolonged in renal impairment (up to 20 hours if CrCl <30 mL/min).
Ciprofloxacin: 50-70% unchanged in urine via glomerular filtration and tubular secretion; 20-35% in feces via biliary and intestinal secretion. Dexamethasone: primarily metabolized, <10% unchanged in urine; biliary/fecal excretion of metabolites.
Renal (approximately 70% unchanged in urine); biliary/fecal (~30%, partly as metabolites and unchanged drug).
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic